Hepion Pharmaceuticals, Inc. (CTRV) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Jun-30-17	Jun-30-16	Jun-30-15	Jun-30-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]		8.1	4.6	7.0	7.4	5.8	5.6	1.4
General and administrative	0.0	8.1	4.6	7.0	7.4	5.8	5.6	1.4
Research and development		12.0	3.2	7.6	13.7	15.0	8.4	0.3
EBITDA [+]		-20.1	-7.7	-14.6	-21.0	-20.8	-13.9	-1.7
EBITDA growth	-100.0%	159.7%	-46.9%		1.0%	49.1%	734.6%
Depreciation and amortization		0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT [+]	0.0	-20.1	-7.8	-14.6	-21.0	-20.8	-14.0	-1.7
EBIT growth	-100.0%	159.3%	-46.8%		1.0%	49.0%	734.9%
Interest expense		0.0	0.6	0.3
Interest expense		0.0	0.6	0.3
Other income (expense), net [+]		-0.1	0.4	4.9	4.2	3.8	-0.4	-3.6
Change in fair value of warrants							-0.4	-3.6
Pre-tax income	0.0	-20.3	-7.9	-10.0	-16.8	-17.0	-14.3	-5.3
Income taxes	0.0	0.0	-0.9	-0.5	-1.9	0.0	0.0	0.0
Tax rate			11.4%	5.4%	11.4%	0.0%	0.0%	0.0%
Net income	0.0	-20.4	-12.5	-17.9	-14.9	-17.0	-14.3	-5.3

Basic EPS [+]		($2.10)	($6.11)	($97.35)	($2.04)	($0.63)	($0.66)	($0.41)
Growth		-65.6%	-93.7%		225.3%	-4.8%	60.1%
Diluted EPS [+]		($2.10)	($6.11)	($97.35)	($2.04)	($0.63)	($0.66)	($0.41)
Growth		-65.6%	-93.7%		225.1%	-4.8%	60.1%

Shares outstanding (basic) [+]		9.7	2.0	0.2	7.3	27.1	21.8	12.8
Growth		373.7%	1011.2%		-73.1%	24.4%	69.7%
Shares outstanding (diluted) [+]		9.7	2.0	0.2	7.3	27.1	21.8	12.8
Growth		373.7%	1011.2%		-73.1%	24.4%	69.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.